Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme a reductase without decreasing cholesterol synthesis

Journal of Immunology

Volumn 179, Issue 6, 2007, Pages 3613-3621

  Blank, Norbert ^a,c   Schiller, Martin ^a   Krienke, Stefan ^a   Busse, Freja ^a   Schätz, Birgit ^b   Ho, Anthony D ^a   Kalden, Joachim R ^b   Lorenz, Hanns Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Universitaetsklinikum Heidelberg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CD69 ANTIGEN; CHOLERA TOXIN B SUBUNIT; GAMMA INTERFERON; GANGLIOSIDE GM1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INTERLEUKIN 2 RECEPTOR ALPHA; LAT PROTEIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE LCK; SUPERANTIGEN; BIOLOGICAL MARKER; CHOLESTEROL; GROWTH INHIBITOR; HEPTANOIC ACID DERIVATIVE; HLA DR ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE (NADPH); IMMUNOSUPPRESSIVE AGENT; PYRROLE DERIVATIVE;

ARTICLE; CALCIUM TRANSPORT; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BINDING; DRUG MECHANISM; HUMAN; HUMAN CELL; LIPID RAFT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MEMBRANE FORMATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PRENYLATION; T LYMPHOCYTE ACTIVATION; ANTIGEN PRESENTING CELL; BIOSYNTHESIS; CALCIUM SIGNALING; CELL CULTURE; CELL MEMBRANE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; IMMUNOLOGY; LEUKEMIA CELL LINE; LYMPHOCYTE ACTIVATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; T LYMPHOCYTE;

ANTIGEN-PRESENTING CELLS; BIOLOGICAL MARKERS; CALCIUM SIGNALING; CELL MEMBRANE; CELL PROLIFERATION; CELLS, CULTURED; CHOLESTEROL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G(M1) GANGLIOSIDE; GROWTH INHIBITORS; HEPTANOIC ACIDS; HLA-DR ANTIGENS; HUMANS; HYDROXYMETHYLGLUTARYL-COA-REDUCTASES, NADP-DEPENDENT; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; JURKAT CELLS; LYMPHOCYTE ACTIVATION; PHOSPHORYLATION; PROTEIN ISOPRENYLATION; PYRROLES; T-LYMPHOCYTES;

EID: 35748945752     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.6.3613     Document Type: Article

References (43)

1. Drevot, P., C. Langlet, X. J. Guo, A. M. Bernard, O. Colard, J. P. Chauvin, R. Lasserre, and H. A. T. He. 2002. TCR signal initiation machinery is preassembled and activated in a subset of membrane rafts. EMBO J. 21: 1899-1908.
2. Simons, K., and D. Toomre. 2000. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1: 31-39.
3. Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. Dustin. 1999. The immunological synapse: a molecular machine controlling T cell activation. Science 285: 221-227.
4. Simons, K., and E. Ikonen. 1997. Functional rafts in cell membranes. Nature 387: 569-572.
5. Pike, L. J. 2003. Lipid rafts: bringing order to chaos. J. Lipid Res. 44: 655-667.
6. Brown, D. A., and E. London. 1997. Structure of detergent-resistant membrane domains: does phase separation occur in biological membranes? Biochem. Biophys. Res. Commun. 240: 1-7.
7. Brown, D. A., and J. K. Rose. 1992. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 68: 533-544.
8. Schuck, S., M. Honsho, K. Ekroos, A. Shevchnko, and K. Simons. 2003. Resistance of cell membranes to different detergents. Proc. Natl. Acad. Sci. USA 100: 5795-5800.
9. Kwak, B., F. Mulhaupt, S. Myit, and F. Mach. 2000. Statins as a newly recognized type of immunomodulator. Nat. Med. 6: 1399-1402.
10. Youssef, S., O. Stuve, J. C. Patarroyo, P. J. Ruiz, J. L. Radosevich, E. M. Hur, M. Bravo, D. J. Mitchell, R. A. Sobel, L. Steinman, and S. S. Zamvil. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84.
11. Aktas, O., S. Waiczies, A. Smorodchenko, J. Dorr, B. Seeger, T. Prozorovski, S. Sallach, M. Endres, S. Brocke, R. Nitsch, and F. Zipp. 2003. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 197: 725-733.
12. Leung, B. P., N. Sattar, A. Crilly, M. Prach, D. W. McCarey, H. Payne, R. Madhok, C. Campbell, J. A. Gracie, F. Y. Liew, and I. B. McInnes. 2003. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 170: 1524-1530.
13. 1 mice. J. Immunol. 173: 7641-7646.
14. Kobashigawa, J. A., S. Katznelson, H. Laks, J. A. Johnson, L. Yeatman, X. M. Wang, D. Chia, P. I. Terasaki, A. Sabad, G. A. Cogert, et al. 1995. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333: 621-627.
15. Wenke, K., B. Meiser, J. Thiery, D. Nagel, W. von Scheidt, K. Krobot, G. Steinbeck, D. Seidel, and B. Reichart. 2003. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 107: 93-97.
16. Abud-Mendoza, C., H. de la Fuente, E. Cuevas-Orta, L. Baranda, J. Cruz-Rizo, and R. Gonzalez-Amaro. 2003. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 12: 607-611.
17. McCarey, D. W., I. B. McInnes, R. Madhok, R. Hampson, O. Scherbakov, I. Ford, H. A. Capell, and N. Sattar. 2004. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 363: 2015-2021.
18. Meroni, P. L., E. Raschi, C. Testoni, A. Tincani, G. Balestrieri, R. Molteni, M. A. Khamashta, E. Tremoli, and M. Camera. 2001. Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2- glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 44: 2870-2878.
19. Neurauter, G., B. Wirleitner, A. Laich, H. Schennach, G. Weiss, and D. Fuchs. 2003. Atorvastatin suppresses interferon-γ-induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin. Exp. Immunol. 131: 264-267.
20. Hillyard, D. Z., A. G. Jardine, K. J. McDonald, and A. J. Cameron. 2004. Fluvastatin inhibits raft dependent Fcγ receptor signalling in human monocytes. Atherosclerosis 172: 219-228.
21. Hillyard, D. Z., A. J. Cameron, K. J. McDonald, J. Thomson, A. MacIntyre, P. G. Shiels, M. Panarelli, and A. G. Jardine. 2004. Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. Atherosclerosis 175: 305-313.
22. Choi, M., S. Rolle, M. Rane, H. Haller, F. C. Luft, and R. Kettritz. 2003. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int. 63: 96-106.
23. Weitz-Schmidt, G., K. Welzenbach, V. Brinkmann, T. Kamata, J. Kallen, C. Bruns, S. Cottens, Y. Takada, and U. Hommel. 2001. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7: 687-692.
24. Blank, N., C. Gabler, M. Schiller, M. Kriegel, J. R. Kalden, and H. M. Lorenz. 2002. A fast, simple and sensitive method for the detection and quantification of detergent-resistant membranes. J. Immunol. Methods 271: 25-35.
25. Wessel, D., and U. I. Flugge. 1984. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal. Biochem. 138: 141-143.
26. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
27. Cordle, A., J. Koenigsknecht-Talboo, B. Wilkinson, A. Limpert, and G. Landreth. 2005. Mechanisms of statin-mediated inhibition of small G-protein function. J. Biol. Chem. 280: 34202-34209.
28. Ghittoni, R., L. Patrussi, K. Pirozzi, M. Pellegrini, P. E. Lazzerini, P. L. Capecchi, F. L. Pasini, and C. T. Baldari. 2005. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J. 19: 605-607.
29. Kurakata, S., M. Kada, Y. Shimada, T. Komai, and K. Nomoto. 1996. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 34: 51-61.
30. Ownby, S. E., and R. J. Hohl. 2003. Isoprenoid alcohols restore protein isoprenylation in a time-dependent manner independent of protein synthesis. Lipids 38: 751-759.
31. Radulovic, L. L., D. D. Cilla, E. L. Posvar, A. J. Sedman, and L. R. Whitfield. 1995. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J. Clin. Pharmacol. 35: 990-994.
32. Koytchev, R., Y. Ozalp, A. Erenmemisoglu, M. J. van der Meer, and R. S. Alpan. 2004. Bioequivalence study of atorvastatin tablets. Arzneim.-Forsch. 54: 573-577.
33. ras activation in T cell CD69 expression. Eur. J. Immunol. 24: 616-620.
34. Sadeghi, M. M., A. Tiglio, K. Sadigh, L. O'Donnell, M. Collinge, R. Pardi, and J. R. Bender. 2001. Inhibition of interferon-γ-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71: 1262-1268.
35. Kuipers, H. F., and P. J. van den Elsen. 2005. Statin and control of MHC2TA gene transcription. Nat. Med. 11: 365-366.
36. Traill, K. N., L. A. Huber, G. Wick, and G. Jurgens. 1990. Lipoprotein interactions with T cells: an update. Immunol. Today 11: 411-417.
37. Cuthbert, J. A., and P. E. Lipsky. 1992. Differential regulation of the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase, synthase, and low density lipoprotein receptor genes. J. Lipid Res. 33: 1157-1163.
38. Viola, A., S. Schroeder, Y. Sakakibara, and A. Lanzavecchia. 1999. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 283: 680-682.
39. Martin, M., H. Schneider, A. Azouz, and C. E. Rudd. 2001. Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function. J. Exp. Med. 194: 1675-1681.
40. Tuosto, L., I. Parolini, S. Schroeder, M. Sargiacomo, A. Lanzavecchia, and A. Viola. 2001. Organization of plasma membrane functional rafts upon T cell activation. Eur. J. Immunol. 31: 345-349.
41. Fra, A. M., E. Williamson, K. Simons, and R. G. Parton. 1994. Detergent-insoluble glycolipid microdomains in lymphocytes in the absence of caveolae. J. Biol. Chem. 269: 30745-30748.
42. Ilangumaran, S., S. Arni, M. Poincelet, J. M. Theler, P. J. Brennan, Nasir-ud-Din, and D. C. Hoessli. 1995. Integration of mycobacterial lipoarabinomannans into glycosylphosphatidylinositol-rich domains of lymphomonocytic cell plasma membranes. J. Immunol. 155: 1334-1342
43. Mielenz, D., C. Vettermann, M. Hampel, C. Lang, A. Avramidou, M. Karas, and H. M. Jack. 2005. Lipid rafts associate with intracellular B cell receptors and exhibit a B cell stage-specific protein composition. J. Immunol. 174: 3508-3517.